JERUSALEM (Reuters) - Israeli medical device maker Alpha Tau Medical said on Thursday it raised $26 million in a funding round from investors including Shavit Capital, Medison Ventures and OurCrowd to help finance global clinical trials.
Tel Aviv, Israel, June 4, 2020 - Alpha Tau Medical, the developer of breakthrough alpha-radiation cancer therapy Alpha DaRT, is pleased to announce the closing of a Series B equity financing of $26 million. Investors in the round included a mix of existing investors fr...
When 78-year-old Israeli cancer patient Lela Parnes stumbled upon the Alpha DaRT treatment in 2017, with information from a friend of hers, she had just received her third diagnosis of cancer in multiple organs, as part of a long journey that had started i...
Tel Aviv, Israel -- Alpha Tau Medical – the developer of breakthrough alpha-radiation cancer therapy Alpha DaRT, and Medison Canada – a fully owned subsidiary of Medison Pharma, are pleased to announce that they have entered into an exclusive distribution arrangement.
On November 28, 2019, the first Alpha DaRT procedure was performed in Russia, at the A. Tsyb Medical Radiological Research Center in Obninsk, in a patient diagnosed with metastatic breast cancer. Radiation Oncologist Dr. Razvan Galalae from Essen, Germany, performed th...
